Zobrazeno 1 - 10
of 133
pro vyhledávání: '"Esther Oomen-de Hoop"'
Autor:
Sophie M. Ernst, Maaike M. Hofman, Tessa E. van der Horst, Marthe S. Paats, Frank W.J. Heijboer, Joachim G.J.V. Aerts, Daphne W. Dumoulin, Robin Cornelissen, Jan H. von der Thüsen, Peter de Bruijn, Esther Oomen-de Hoop, Ron H.J. Mathijssen, Stijn L.W. Koolen, Anne-Marie C. Dingemans
Publikováno v:
EBioMedicine, Vol 102, Iss , Pp 105074- (2024)
Summary: Background: Sotorasib given after immunotherapy could put patients at increased risk of hepatotoxicity. Therefore, there is a need to gain insight into the potential correlation between anti-PD-(L)1 treatment, anti-PD-(L)1 concentrations, so
Externí odkaz:
https://doaj.org/article/a26effef666d4b159c43d8ae59e8c674
Autor:
Sanne M. Buijs, Daan C.H. van Dorst, Marieke J.H.A. Kruip, Rob F.P. van den Akker, Ka L. Cheung, Robert Porrazzo, Esther Oomen-de Hoop, Agnes Jager, Stijn L.W. Koolen, Jorie Versmissen, A.H. Jan Danser, Henri H. Versteeg, Mettine H.A. Bos, Ron H.J. Mathijssen
Publikováno v:
Biomedicine & Pharmacotherapy, Vol 170, Iss , Pp 115969- (2024)
Background: Tamoxifen is an effective treatment for primary breast cancer but increases the risk for venous thromboembolism. Tamoxifen decreases anticoagulant proteins, including antithrombin (AT), protein C (PC) and tissue factor (TF) pathway inhibi
Externí odkaz:
https://doaj.org/article/36f8d4d8416b471296eb3d65386acbe7
Autor:
Marjolijn M. Ladan, Titia G. Meijer, Nicole S. Verkaik, Cecile de Monye, Linetta B. Koppert, Esther Oomen-de Hoop, Carolien H. M. van Deurzen, Roland Kanaar, Julie Nonnekens, Dik C. van Gent, Agnes Jager
Publikováno v:
npj Breast Cancer, Vol 9, Iss 1, Pp 1-7 (2023)
Abstract We developed a functional ex vivo anthracycline-based sensitivity test. Surgical resection material of primary breast cancer (BC) was used to determine criteria for the ex vivo sensitivity assay based on morphology, proliferation and apoptos
Externí odkaz:
https://doaj.org/article/131ad1d936bc40268bf604058db3be8d
Autor:
Khrystany T. Isebia, Bianca Mostert, Teoman Deger, Jaco Kraan, Vanja deWeerd, Esther Oomen‐de Hoop, Paul Hamberg, Brigitte C. M. Haberkorn, Helgi H. Helgason, Ronald deWit, Ron H. J. Mathijssen, Martijn P. Lolkema, Saskia M. Wilting, Job vanRiet, John W. M. Martens
Publikováno v:
Molecular Oncology, Vol 17, Iss 9, Pp 1898-1907 (2023)
Multiple prognostic biomarkers, including circulating tumour cell (CTC) counts, exist in metastatic castration‐resistant prostate cancer (mCRPC) patients, but none of them have been implemented into daily clinical care. The modified fast aneuploidy
Externí odkaz:
https://doaj.org/article/5586ded94d52426a8e1b34ae1e5d9078
Autor:
Sanne M. Buijs, C. Louwrens Braal, Stefan A. J. Buck, Noud F. van Maanen, Lonneke M. van der Meijden-Erkelens, Heleen A. Kuijper-Tissot van Patot, Esther Oomen-de Hoop, Lotte Saes, Sophia J. van den Boogerd, Liesbeth E. M. Struik, Quirine C. van Rossum-Schornagel, Ron H. J. Mathijssen, Stijn L. W. Koolen, Agnes Jager
Publikováno v:
npj Breast Cancer, Vol 9, Iss 1, Pp 1-7 (2023)
Abstract Tamoxifen may lead to bothersome side effects contributing to non-compliance and decreased quality of life. Patients searching for relief are increasingly turning to cannabinoids such as CBD-oil. However, CBD-oil might affect tamoxifen pharm
Externí odkaz:
https://doaj.org/article/270e89bb85c04654be454a2dba613f34
Autor:
Stefan A.J. Buck, Marinda Meertens, Frederiek M.F. van Ooijen, Esther Oomen-de Hoop, Evert de Jonge, Marieke J.H. Coenen, Andries M. Bergman, Stijn L.W. Koolen, Ronald de Wit, Alwin D.R. Huitema, Ron H.N. van Schaik, Ron H.J. Mathijssen
Publikováno v:
Biomedicine & Pharmacotherapy, Vol 169, Iss , Pp 115890- (2023)
Extragonadal androgens play a pivotal role in prostate cancer disease progression on androgen receptor signaling inhibitors (ARSi), including abiraterone and enzalutamide. We aimed to investigate if germline variants in genes involved in extragonadal
Externí odkaz:
https://doaj.org/article/6d3d5ec4ff3b487a8575fbe70cc76c22
Autor:
Daan A.C. Lanser, Maud B.A. Van der Kleij, G.D. Marijn Veerman, Neeltje Steeghs, Alwin D.R. Huitema, Ron H.J. Mathijssen, Esther Oomen-de Hoop
Publikováno v:
Biomedicine & Pharmacotherapy, Vol 163, Iss , Pp 114823- (2023)
Polypharmacy is becoming increasingly prevalent in society. Patients with polypharmacy are at greater risk for drug-drug interactions, which can influence the efficacy of treatment. Especially, in oncology this is a concern since neoplasms are increa
Externí odkaz:
https://doaj.org/article/a1658905099e486c8a6f15fb306183c1
Autor:
G.D. Marijn Veerman, Rene J. Boosman, Merel Jebbink, Esther Oomen-de Hoop, Anthonie J. van der Wekken, Idris Bahce, Lizza E.L. Hendriks, Sander Croes, Christi M.J. Steendam, Evert de Jonge, Stijn L.W. Koolen, Neeltje Steeghs, Ron H.N. van Schaik, Egbert F. Smit, Anne-Marie C. Dingemans, Alwin D.R. Huitema, Ron H.J. Mathijssen
Publikováno v:
EClinicalMedicine, Vol 59, Iss , Pp 101955- (2023)
Summary: Background: Central nervous system (CNS) metastases are present in approximately 40% of patients with metastatic epidermal growth factor receptor-mutated (EGFRm+) non-small cell lung cancer (NSCLC). The EGFR-tyrosine kinase inhibitor osimert
Externí odkaz:
https://doaj.org/article/3a9954ccf1454c0c889fa14273839a4e
Autor:
Mirjam de With, Leni van Doorn, Demi C. Maasland, Tessa A.M. Mulder, Esther Oomen-de Hoop, Bianca Mostert, Marjolein Y.V. Homs, Samira El Bouazzaoui, Ron H.J. Mathijssen, Ron H.N. van Schaik, Sander Bins
Publikováno v:
Biomedicine & Pharmacotherapy, Vol 159, Iss , Pp 114232- (2023)
Aim of the study: Occurrence of hand-foot syndrome (HFS) during capecitabine treatment often results in treatment interruptions (26 %) or treatment discontinuation (17 %), and can severely decrease quality of life. In this study, we investigated whet
Externí odkaz:
https://doaj.org/article/22d712ca5f2d4b6f9d5ea8fc0cd5da1f
Autor:
Daan C. H. van Dorst, Sumeyye Kabadayi, Esther Oomen‐de Hoop, A.H. Jan Danser, Ron H. J. Mathijssen, Jorie Versmissen
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 12, Iss 1 (2023)
Background Anti‐cancer vascular endothelial growth factor inhibitors (VEGFI) frequently induce a rise in blood pressure (BP). The most effective treatment of this BP rise is currently unknown, and risk factors and its association with survival rema
Externí odkaz:
https://doaj.org/article/59d3fa5ccc3d4b688b07134a4440606a